Previous 10 | Next 10 |
EVANSTON, Ill., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell shares of its common stock...
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will pre...
EVANSTON, Ill., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a presentation highlighting preclinical data on its novel NM...
Aptinyx (NASDAQ: APTX ) initiates a Phase 2 clinical study of its NMDA receptor modulator, NYX-458, for the treatment of mild cognitive impairment associated with Parkinson’s disease. More news on: Aptinyx Inc., Healthcare stocks news, Stocks on the move, Read more ...
Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across innovative CNS pipeline with data readouts expected over next 12 to 24 months ...
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the follo...
Aptinyx Inc. (APTX) Q3 2019 Earnings Conference Call November 12, 2019 17:30 ET Company Participants Nick Smith - Senior Director, Corporate Development and Investor Relations Norbert Riedel - President and Chief Executive Officer Ashish Khanna - Chief Financial Officer and Chief...
Aptinyx (NASDAQ: APTX ): Q3 GAAP EPS of -$0.44 in-line. More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated two Phase 2 studies of NYX-2925 in chronic pain conditions On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates Conference call today at 5:00 p.m. EST EVANSTON, Ill., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq...
200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications Top-line efficacy and safety data anticipated in late 2020 or early 2021 for painful DPN and 1H 2021 for fibromyalgia Studies...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...